These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 30652043)

  • 21. Efficacy of tumor necrosis factor inhibitor combined with intra-articular injection of triamcinolone acetonide in the treatment of refractory rheumatoid arthritis synovitis: a retrospective study.
    Chen Y; Yuan J; Cai Z; Ma Y
    Clin Rheumatol; 2023 Jul; 42(7):1793-1799. PubMed ID: 36864226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration.
    Ahmed M; Luggen M; Herman JH; Weiss KL; Decourten-Myers G; Quinlan JG; Khanna D
    J Rheumatol; 2006 Nov; 33(11):2344-6. PubMed ID: 16981287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolated rheumatoid arthritis-associated cerebral vasculitis: a diagnostic challenge.
    Guadalupe Loya-de la Cerda D; Avilés-Solís JC; Delgado-Montemayor MJ; Camara-Lemarroy CR; Galarza-Delgado DÁ
    Joint Bone Spine; 2013 Jan; 80(1):88-90. PubMed ID: 22858148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
    Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
    Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extra-articular involvement of rheumatoid arthritis in three seropositive patients in the absence of initial joint involvement.
    Chirila RM; Berianu F; Abril A; Butendieck RR
    Immun Inflamm Dis; 2021 Dec; 9(4):1613-1617. PubMed ID: 34473908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rheumatoid arthritis with pachymeningitis - a case presentation and review of the literature.
    Joshi S; Masiak A; Zdrojewski Z
    Reumatologia; 2020; 58(2):116-122. PubMed ID: 32476685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.
    Buttgereit F; Aelion J; Rojkovich B; Zubrzycka-Sienkiewicz A; Chen S; Yang Y; Arikan D; D'Cunha R; Pang Y; Kupper H; Radstake T; Amital H
    Arthritis Rheumatol; 2023 Jun; 75(6):879-889. PubMed ID: 36512671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab-induced sarcoidosis-like reaction involving oral cavity in rheumatoid arthritis: a case-based review.
    Rodrigues-Fernandes CI; Migliorati CA; Gueiros LAM; de Lima Morais TM; Vargas PA; de Almeida OP; Lopes MA; Santos-Silva AR
    Clin Rheumatol; 2021 Sep; 40(9):3833-3839. PubMed ID: 33629203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of tumor necrosis factor-α inhibitors and liver cirrhosis in patients with rheumatoid arthritis: A nationwide population-based nested case-control study.
    Chen DY; Lin CH; Chen HH; Tang KT
    Int J Rheum Dis; 2022 Mar; 25(3):327-334. PubMed ID: 34994523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
    Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
    JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical features of rheumatoid arthritis.
    Grassi W; De Angelis R; Lamanna G; Cervini C
    Eur J Radiol; 1998 May; 27 Suppl 1():S18-24. PubMed ID: 9652497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of tumor necrosis factor α in rheumatoid arthritis.
    Kulp W; Corzillus M; Greiner W; Pientka L; Siebert U; von der Schulenburg JM; Wasem J
    GMS Health Technol Assess; 2005 Dec; 1():Doc12. PubMed ID: 21289933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ; Virkki LM; Malmivaara A; Konttinen YT; Nordström DC; Blom M
    PLoS One; 2012; 7(1):e30275. PubMed ID: 22272322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
    Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
    J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
    Aterido A; Cañete JD; Tornero J; Blanco F; Fernández-Gutierrez B; Pérez C; Alperi-López M; Olivè A; Corominas H; Martínez-Taboada V; González I; Fernández-Nebro A; Erra A; López-Lasanta M; López Corbeto M; Palau N; Marsal S; Julià A
    Front Immunol; 2019; 10():1459. PubMed ID: 31312201
    [No Abstract]   [Full Text] [Related]  

  • 36. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis.
    Conforti A; Di Cola I; Pavlych V; Ruscitti P; Berardicurti O; Ursini F; Giacomelli R; Cipriani P
    Autoimmun Rev; 2021 Feb; 20(2):102735. PubMed ID: 33346115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sweet's Syndrome in a Patient With Seropositive Rheumatoid Arthritis After Starting Adalimumab: Is Sweet's Syndrome Related to Rheumatoid Arthritis or Is It the Paradoxical Effect of Adalimumab?
    Paul P; Walker CP; Paul M; Dey D
    Cureus; 2021 Aug; 13(8):e16804. PubMed ID: 34513410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Cyclic Citrullinated Peptide Antibody-Positive Meningoencephalitis in the Preclinical Period of Rheumatoid Arthritis.
    Shibahara T; Matsushita T; Matsuo R; Fukushima Y; Fukuda K; Sugimori H; Kamouchi M; Kitazono T; Ago T
    Case Rep Neurol; 2016; 8(2):156-160. PubMed ID: 27721779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.